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Theconceptof ‘‘metabolic inflexibility’’wasfirst intro-
duced to describe the failure of insulin-resistant
humansubjects toappropriately adjustmitochondrial
fuel selection in response to nutritional cues. This
phenomenonhas sincegained increasing recognition
as a core component of the metabolic syndrome, but
the underlying mechanisms have remained elusive.
Here, we identify an essential role for the mitochon-
drial matrix enzyme, carnitine acetyltransferase
(CrAT), in regulating substrate switching and glucose
tolerance. By converting acetyl-CoA to its membrane
permeant acetylcarnitine ester, CrAT regulates mito-
chondrial and intracellular carbon trafficking. Studies
in muscle-specific Crat knockout mice, primary
human skeletal myocytes, and human subjects
undergoing L-carnitine supplementation support a
model wherein CrAT combats nutrient stress, pro-
motes metabolic flexibility, and enhances insulin
action by permitting mitochondrial efflux of excess
acetyl moieties that otherwise inhibit key regulatory
enzymes such as pyruvate dehydrogenase. These
findings offer therapeutically relevant insights into
the molecular basis of metabolic inflexibility.
INTRODUCTION
In light of the current obesity epidemic, research aimed at under-
standing and therapeutically targeting the interplay between
intramuscular lipid balance, mitochondrial energetics, and
insulin action has taken on heightened urgency. This complex
topic has been positioned at the forefront of diabetes research
for the past fifty years. In 1963 Randle and colleagues proposed
the glucose-fatty acid cycle to explain lipid-induced suppression
of muscle glucose disposal (Randle et al., 1963). A central tenant
of this model is that byproducts of fatty acid b-oxidation,
including acetyl-CoA, NADH, and ATP, act as potent allosteric764 Cell Metabolism 15, 764–777, May 2, 2012 ª2012 Elsevier Inc.inhibitors of glycolysis and pyruvate dehydrogenase (PDH), a
unidirectional mitochondrial complex that couples glycolysis to
glucose oxidation. Inhibition of PDH activity was presumed to
slow glycolytic flux, resulting in negative feedback on glucose
uptake. Although numerous studies in humans, animals, and
cultured cells have since confirmed that heavy supply of fatty
acids suppresses glucose oxidation, the precise role of the
glucose-fatty acid cycle in the etiology of glucose intolerance
and insulin resistance remains a matter of controversy (Muoio,
2010; Samuel et al., 2010).
In recent years the substrate competition theory of insulin
resistance has been challenged by alternative hypotheses
centered on the idea that insufficient b-oxidation contributes to
tissue accumulation of lipid signaling molecules that antagonize
insulin signal transduction (Giancaterini et al., 2000; Samuel
et al., 2010). Whereas the past decade of diabetes research
has focused heavily on this so-called ‘‘lipotoxicity’’ paradigm,
interest in the importance of mitochondrial fuel selection has
been rekindled by studies showing that obese and/or diabetic
humans fail to shift from fatty acid to glucose oxidation during
the transition from fasting to feeding (Kelley and Mandarino,
2000). This phenomenon of ‘‘metabolic inflexibility’’ has gained
increasing recognition as a hallmark of cardiometabolic disor-
ders (Thyfault et al., 2006) but remains poorly understood at
a molecular level. Additionally, the advent of metabolomics
has provided new evidence linking muscle insulin resistance to
overburdened mitochondria, as suggested by high rates of
incomplete fat oxidation and tissue accumulation of mitochon-
drial-derived acylcarnitine metabolites detected in rodent
models of obesity and diabetes (Koves et al., 2008). Notably, in
some instances the obesity-associated accumulation of long
and medium chain acylcarnitines in muscle was accompanied
by a decline in free carnitine (Noland et al., 2009), whereas die-
tary L-carnitine supplementation enhanced whole body glucose
tolerance and rescued metabolic flexibility (Noland et al., 2009;
Power et al., 2007). Taken together, these findings lend merit
to the glucose-fatty acid cycle as originally proposed by Randle
and suggest a role for L-carnitine and acylcarnitine production in
regulating glucose homeostasis.
L-carnitine is a conditionally essential nutrient that serves as
a substrate for a family of acyltransferase enzymes that catalyze
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carnitine. Unlike their acyl-CoA precursors, acylcarnitines can
traverse cellular membranes; thus, the interconversion of these
molecules can impact cellular and intertissue carbon trafficking.
The most prominent members of this family, carnitine palmitoyl-
transferase (CPT1) and CPT2, are localized on the outer and
inner mitochondrial membranes, respectively, where together
with carnitine acylcarnitine translocase they permit import of
long chain fatty acyl-CoAs into the mitochondrial matrix for
b-oxidation (Bieber, 1988; McGarry et al., 1991; Ramsay and
Zammit, 2004). A third member of this family, carnitine acetyl-
transferase (CrAT), resides principally within the mitochondrial
matrix where it acts selectively on short chain acyl-CoAs (Bieber,
1988; Cordente et al., 2004). In contrast to CPT1 and CPT2, the
precise function of CrAT and its potential relevance to metabolic
disease is poorly understood. Importantly however, a role for
this enzyme in defending glucose homeostasis was strongly
implicated in the aforementioned animal studies, wherein the
therapeutic benefits of L-carnitine supplementation corre-
spondedwith robust tissue efflux and urinary excretion of acetyl-
carnitine (the major product of CrAT) (Noland et al., 2009; Power
et al., 2007). Herein, we sought to test the hypothesis that CrAT
plays a key role in regulating systemic glucose tolerance in both
rodents and humans. In aggregate, our results provide definitive
evidence that CrAT impacts whole body glucose homeostasis,
and that muscle-specific loss of function compromises meta-
bolic control in a manner that resembles the insulin-resistant
state.
RESULTS
Tissue-Specific Targeting of CrAT Activity
Considering that CrAT is most abundant in skeletal muscle and
heart (Marquis and Fritz, 1965; Noland et al., 2009) and because
these tissues are presumed to contribute substantially to the
circulating pool of acetylcarnitine, we generatedmuscle-specific
crat knockout mice (CratM/) by breeding animals harboring
a floxed allele of the crat gene to those expressing Cre recombi-
nase under the control of the muscle creatine kinase (MCK)
promoter (Figure 1A and Supplemental Experimental Proce-
dures). Analysis of crat abundance by qRT-PCR, Western blot,
and enzymatic activity confirmed loss of function in skeletal
muscle and heart without effects on expression or activity in
other tissues (Figures 1B–1D). Figure 1E shows a near-complete
loss (94%–98%) of acyltransferase activity using various short
chain acyl-CoA substrates in isolatedmitochondria from skeletal
muscle of CratM/ compared to control littermates (Cratfl/fl).
The high (54%) residual activity with octanoyl-CoA (C8) is likely
attributable to carnitine octanoyltransferase and/or palmitoyl-
transferase 2 (Ramsay and Zammit, 2004).
Muscle-Specific Deletion of CrAT Alters Whole Body
Energy Metabolism
Between five and twenty weeks of age CratM/ mice and
control littermates (Cratfl/fl) fed a low fat diet gained total body
weight and fat pad mass at similar rates (Figures 2A and 2B);
however, when challenged with a high fat diet, CratM/ mice
gained more body weight and more fat mass than the control
group. Interestingly, despite normal body weight when feedingCon the low fat diet, blood glucose levels were higher in the
CratM/, both at baseline and throughout an intraperitoneal
glucose tolerance test (Figures 2C and S1). The glucose intol-
erant phenotype of CratM/ mice was further exacerbated by
high fat feeding (Figure 2D). Likewise, lowering of blood glucose
in response to an acute insulin bolus was blunted in the CratM/
mice, regardless of diet (Figures 2E and S1).
To avoid potential confounding effects of increased body
weight and adiposity, further analyses of the CratM/ mice
were performed in animals maintained on a low fat diet. Plasma
triglycerides (TAG)andnonesterified fattyacids (NEFAs;Figure2F)
were lower in the knockout mice, suggesting potential alterations
in lipid clearance and/or utilization. Whole body indirect calorim-
etry did not reveal differences in 24 hr average RER or energy
expenditurebetweenknockoutandcontrolmice (datanot shown).
However, the increase in whole body carbohydrate oxidation that
typically occurs in response to an insulin challenge (Figure 2G) or
during the fasting-to-fed transition (Figures S1E and S1F) was
diminished in the CratM/ mice, implying that these mice are
lessmetabolically flexible. Despite clear evidenceof glucose intol-
erance in the CratM/mice, insulin-mediated phosphorylation of
Akt (Figure 2H) and GSK-3b (not shown) were similar between
genotypes, implicating other sites of dysregulation.
Acylcarnitine Profiling of CratM–/– Mice
Muscle-specific loss of crat lowered acetylcarnitine levels 37%–
50% in plasma (Figure 3A), skeletal muscle (SkM; Figure 3B), and
heart (Figure 3C). These reductions were less than predicted
assuming that muscle is the major source of circulating acetyl-
carnitine. Likewise, tissue and plasma levels of propionylcarni-
tine (C3), another major product of CrAT, were only partially
reduced, and butyrylcarnitine (C4) was actually elevated in the
heart. Together, these findings indicate that tissues other than
muscle contribute substantially to the circulating pool of short
chain acylcarnitines. Notably, crat deficiency provoked marked
accumulation of several medium and long chain acylcarnitines
in skeletal muscle and to a lesser degree in heart, without
affecting plasma levels of these metabolites. Additionally,
several short, medium, and long chain acyl-CoA species were
elevated in CratM/ hearts (Figure S2).
CrAT Deficiency Disrupts Mitochondrial Pyruvate
Metabolism without Inhibiting Respiratory Function
The foregoing accumulation of long and medium chain acylcar-
nitines in muscle of CratM/ mice might reflect a distal bottle-
neck in b-oxidation, and/or heavier mitochondrial influx and
catabolism of lipid substrate in muscle. To address the former
possibility we evaluated the impact of crat deficiency on mito-
chondrial content and/or function. Tissue abundance of
prominent mitochondrial marker proteins such as citrate syn-
thase and electron transport complexes I, II, and V was similar
between genotypes (Figure 4A). Likewise, citrate synthase
activity measured in skeletal muscle mitochondrial lysates was
unchanged in the knockout mice (Figure 4B). Assessment of
oxygen consumption in mitochondria respiring under state 3
and state 4 conditions in the presence of pyruvate/malate was
also unremarkable, regardless of carnitine provision (Figure 4C).
By contrast, when this assaywas performedwith pyruvate as the
only carbon source (i.e., omitting malate as an anapleroticell Metabolism 15, 764–777, May 2, 2012 ª2012 Elsevier Inc. 765
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Figure 1. Generation of Mice with Muscle-Specific CrAT Deficiency
(A–E) (A) shows the genetic strategy for generating mice with muscle-specific ablation of CrAT (CratM/). Tissue-specific deletion was confirmed by analyzing
CrAT mRNA (B), protein (C), and enzyme activity (D) in multiple tissues (n = 3–6/group). Enzymatic activity in isolated mitochondrial lysates from mixed
gastrocnemius skeletal muscle (SkM) was measured with several short and medium chain acyl-CoAs as substrates (E; n = 6/group).
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CrAT Regulates Metabolic Flexibilitysubstrate), addition of carnitine increased state 3 respiration
4.3-fold in mitochondria from Cratfl/fl mice, whereas this effect
was completely absent in the crat null mitochondria (Figure 4D).
We surmised that the carnitine-mediated increase in respiration
might be due to CrAT-dependent stimulation of PDH, a reaction
that produces NADH substrate for complex I of the electron
transport chain. This possibility was confirmed via direct assess-
ment of PDH activity, which was stimulated 1.8-fold by carnitine
in the control groupwhereas a 33% inhibition occurred in the crat
null mitochondria (Figure 4E). In contrast to muscle, hepatocytes
use acetyl-CoA as a substrate for ketogenesis and de novo lipo-
genesis. Thus, in the liver, CrAT is absent from the mitochondrial
compartment (Figure S3) and is instead localized mainly to the
peroxisomes (Beenakkers and Klingenberg, 1964; Bloisi et al.,
1990). Consistent with results in muscles from CratM/ mice,
carnitine failed to stimulate PDH activity in liver mitochondria
(Figure 4F). Acetyl-CoA antagonizes PDH activity through direct766 Cell Metabolism 15, 764–777, May 2, 2012 ª2012 Elsevier Inc.allosteric inhibition of the enzyme complex and by stimulating
a family of PDH kinases that inactive the E1a catalytic subunit
via phosphorylation at multiple serine residues (Sugden and Hol-
ness, 2003). Accordingly, we examined E1a phosphorylation at
Ser232, Ser293, and Ser300 in muscles from knockout and control
mice, but differences between genotypes were not detected (not
shown).
To assess trafficking of glucose-derived carbons in intact
skeletal muscle we incubated isolated soleus muscles with
[13C6]glucose followed by mass spectrometry-based analysis
of acylcarnitines. In soleus muscles from Cratfl/fl mice the [13C2]
acetylcarnitine species, which originated from PDH-generated
acetyl-CoA, accounted for 20% and 30% of the total acetylcar-
nitine content under basal and insulin-stimulated conditions,
respectively (Figure 4G). Interestingly, [13C2]acetylcarnitine
was also detected in the crat null muscles, which could be attrib-
utable to residual CrAT activity in whole muscle tissue and/or
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Figure 2. Muscle-Specific CrAT Deficiency Affects Whole Body Metabolic Homeostasis
(A–H) CratM/mice and control (Cratfl/fl) littermates were fed either a 10% fat (Low Fat) or a 45% fat (High Fat) diet beginning at 5 weeks of age. Body weight (A)
and fat mass (B) were measured every two weeks (n = 10–13/group). Glucose tolerance tests were performed using 40 mg glucose/mouse during low fat diet
(C) or 20 mg glucose/mouse during high fat diet (D) (n = 10/group). For insulin tolerance tests (E) blood glucose levels were measured 10 min after injection of
0.04U insulin/mouse (low fat diet) or 0.08U/mouse (high fat diet) in fed mice (n = 10/group). The following measures were from mice fed a low fat diet. Plasma
triglycerides (TAG) and nonesterified fatty acids (NEFA) weremeasured following a 4 hr fast (F; n = 12/group). Following a 7 day acclimatization period, respiratory
exchange ratio (RER) was monitored by indirect calorimetry immediately after an insulin injection of 0.04 U/mouse (G). Insulin signaling (Akt total, pThr308,, and
pSer473) was measured using lysates prepared from gastrocnemius muscles collected 10 min after insulin injection (H). Quantified bands were normalized to
a MemCode loading control and phosphorylated proteins were expressed relative to total Akt. * Genotype effect (p < 0.05) detected by Student’s t test.
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the total [13C2]acetylcarnitine produced by the Crat
fl/fl muscles
was present in the incubation buffer (Figure 4H). In the control
group, [13C2]acetylcarnitine accounted for 63% of total acetyl-Ccarnitine efflux, and absolute quantities were 692% of those
measured in the incubation buffer from CratM/muscles. These
results confirm an essential role for CrAT in permitting tissue
efflux of PDH-derived acetylcarnitine.ell Metabolism 15, 764–777, May 2, 2012 ª2012 Elsevier Inc. 767
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Figure 3. Free Carnitine and Acylcarnitine Profiling in CratM–/– Mice
(A–C) Tissue and blood specimens were obtained from anesthetized mice (n = 6-12/group) following a 4 hr fast. Free carnitine and acylcarnitine levels in plasma
(A), gastrocnemius muscle (SkM; B), and heart (C) were measured by mass spectrometry. The acyl chain length (C) is denoted by the corresponding metabolite
number (e.g., C0 = free carnitine, C2 = acetylcarnitine; C3 = proprionylcarnitine). Data are expressed as mean ± SEM. * Genotype effect (p < 0.05) detected by
Student’s t test.
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We next questioned whether the absence of CrAT affects fatty
acid catabolism in isolated mitochondria exposed to moderate
(100 mM) or high (300 mM) concentrations of [1-14C]palmitate.
Rates of 14CO2 production were 16%–18% greater in isolated
muscle mitochondria from CratM/ compared to Cratfl/fl mice
(Figures 5A and 5B). The difference between genotypes was
amplified by the addition of 200mM pyruvate, which inhibited
fat oxidation more robustly in the control group (Figures 5A
and 5B). To mimic the metabolic transition between fasting
and feeding we evaluated dose-dependent pyruvate inhibition
of fat oxidation. Absolute rates of palmitate oxidation were
higher in the crat null mitochondria at nearly every dose of pyru-
vate. Moreover, crat deficiency resulted in a statistically signifi-
cant rightward shift in the IC50 of pyruvate, an outcome that
was exacerbated by increasing the palmitate concentration
(Figures 5C and 5D, respectively). We then evaluated oxidation
of [1-14C]oleate in intact mouse soleus muscles incubated ex-
vivo under basal and insulin-stimulated conditions. Insulin sup-
pressed soleus muscle fat oxidation in both groups. Two-way
ANOVA revealed a main effect of the crat null genotype, which
again corresponded with increased fat catabolism (Figure 5E).
Likewise, ablation of CrAT increased soleus muscle content of
medium and long chain acylcarnitines, and largely abolished
the insulin-induced lowering of these species that was evident
in the control group (Figures 5F and 5G). Thus, crat deficiency768 Cell Metabolism 15, 764–777, May 2, 2012 ª2012 Elsevier Inc.lowered mitochondrial and tissue efflux of glucose-derived
carbons (Figure 4) while increasing rates of b-oxidation. These
conditions are likely to promote intramitochondrial accumulation
of fatty acyl-CoAs, giving rise to medium and long chain acylcar-
nitine species.
CrAT Counterregulates Glucose and Fatty Acid
Metabolism in Cultured Myocytes
To gain further evidence that CrAT plays a direct role in counter-
regulating glucose and fatty acid metabolism we performed
loss- and gain-of-function experiments using recombinant
adenoviruses engineered to silence (rAd-shCrat) or overexpress
(rAd-Crat) the enzyme in primary human myocytes. Treatment of
differentiated human myotubes with the rAd-shCrat virus
decreased mRNA levels 60%–80% (not shown), lowered CrAT
specific activity 60% and reduced cellular export of acetylcarni-
tine by 47% (Figure 6A). This partial loss of Crat activity led to a 2-
fold increase in oleate oxidation and a modest but significant
13% decrease in uptake of [3H]-2-deoxy-glucose(Figure 6B).
Interestingly, this suppression of glucose uptake in the CrAT
knockdown group was exacerbated by acute lipid exposure,
both in the absence and presence of insulin (Figure S4).
Conversely, treatment of human myotubes with rAd-Crat re-
sulted in a dose-dependent induction of enzyme activity along
with a progressive decline in complete oxidation of oleate,
whereas production of acid soluble metabolites (an index of
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Figure 4. CrAT Regulates PDH Activity
(A–H) Gastrocnemius muscles were harvested after a 4 hr fast, and lysates were prepared for immunoblot analysis of the mitochondrial marker protein, citrate
synthase (CS), and electron transport chain complexes I, II, and V (A). Mitochondria were isolated from gastrocnemius muscles and a portion of the suspension
was used to assess citrate synthase activity (B; n = 12). State 3 and state 4mitochondrial respiration rates weremeasured using BDOxygenBiosensor plates after
addition of 10 mM pyruvate and 5 mM malate ± 1 mM carnitine (C; n = 6). RCR values were 7.2–7.6 for all groups. State 3 respiration was also measured with
10 mM pyruvate ± 1 mM carnitine (D; n = 6). PDH activity was determined by measuring 14CO2 produced from 1 mM [1-
14C]pyruvate ± 5 mM carnitine in isolated
muscle mitochondria from Cratfl/fl and CratM/ mice (E; n = 6). The acute effect of 5 mM carnitine on PDH activity was evaluated in mitochondria from rat
gastrocnemius muscle compared to rat liver (n = 3) (F). Soleus muscles (n = 6) were incubated 2 hr with 10 mM [13C6]glucose and 200 mM fatty acid ± 100 nM
insulin, followed by LCMS-basedmass analysis of [12C]acetylcarnitine (C2), [13C2]acetylcarnitine ([
13C2]C2), and total acetylcarnitine (C2+([
13C2]C2) in the muscle
tissue (G) and incubation buffer (H). * Genotype and # carnitine effects (p < 0.05) detected by Student’s t test.
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CrAT Regulates Metabolic Flexibilityincomplete fat oxidation) was unchanged (Figure 6C). Treatment
with the rAd-b-gal control virus had no effect. The decline in
complete fat oxidation was accompanied by enhanced cellular
acetylcarnitine efflux and increased PDH activity (Figure 6D).CWe next questioned whether CrAT acts exclusively on
acetyl-CoA derived from the PDH complex. On the contrary,
experiments in primary human skeletal myotubes exposed to
[13C6]glucose or [
13C16]palmitate showed that CrAT can useell Metabolism 15, 764–777, May 2, 2012 ª2012 Elsevier Inc. 769
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Figure 5. CrAT Deficiency Promotes Fat Oxidation
(A–G) Fatty acid oxidation to CO2 was measured in isolated muscle (gastrocnemius) mitochondria exposed to moderate (100 mM; A) or high (300 mM; B) doses of
[1-14C]palmitate ± 200 mM pyruvate (n = 12). Dose-dependent pyruvate inhibition of fatty acid oxidation was measured during exposure to 100 mM (C) or 300 mM
(D) [1-14C]palmitate. Results were normalized to basal oxidation rates and IC50 values for the inhibitory effect of pyruvate on palmitate oxidation were calculated
using GraphPad Prism software. Total oxidation of 500 mM [1-14C]oleate (E) wasmeasured in intact soleusmuscles (n = 6) incubated 2 hr in amodified KHB buffer
containing 5 mM glucose ± 100 nM insulin (E). Soleus muscles (n = 6) were incubated 2 hr with 10 mM [13C6]glucose and 200 mM fatty acid ± 100 nM insulin,
followed by LCMS-based mass analysis of medium (F) and long chain (G) acylcarnitines. Data are expressed as mean ± SEM. Main effects of insulin (^) and
genotype (#) were detected by two-way ANOVA, p < 0.05; * post hoc test for genotype. Two-way ANOVA and MANOVA revealed main effects of insulin and
genotype on the medium/long chain acylcarnitine profiles; symbols were omitted for simplicity.
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CrAT Regulates Metabolic Flexibilityacetyl-CoA originating from either glucose or fatty acid (Fig-
ure 6E). Addition of fatty acid to the culture medium caused a
pronounced shift in the carbon source of acetylcarnitine (in favor
of fatty acid) (Figures S5A–S5C), thus highlighting yet another770 Cell Metabolism 15, 764–777, May 2, 2012 ª2012 Elsevier Inc.way in which lipids antagonize muscle glucose metabolism.
CrAT overexpression increased production of both glucose-
and fatty acid-derived acetylcarnitine, but did not affect the
relative enrichment of [13C], regardless of the carbon source
Cell Metabolism
CrAT Regulates Metabolic Flexibility(Figure 5C). Also noteworthy, incorporation of [13C16]palmitate
into [U-13C]-labeled long and medium chain acylcarnitines was
either unaffected or increased by CrAT overexpression (Fig-
ure 6F). Taken together, these data strongly suggest that
CrAT-mediated lowering of fat oxidation to CO2 (Figure 6C)
was not secondary to CPT1 inhibition, but instead due to rerout-
ing of fatty acid-derived acetyl-CoA away from the TCA cycle
and toward acetylcarnitine efflux (Figure 6G).
Carnitine Supplementation Improved Glucose
Metabolism in Insulin-Resistant Human Subjects
A key question is whether the foregoing findings in animal and
cell culture models translate to humans. Real-time PCR analysis
showed that CrAT gene expression is perturbed by metabolic
disease, as mRNA abundance was 80% lower in skeletal muscle
from human patients with type 2 diabetes as compared to
normal weight or moderately obese subjects (Figure S6 and
Table S1). We then conducted a pilot study to assess the poten-
tial therapeutic actions of L-carnitine supplementation in older
aged subjects with modestly elevated fasting blood glucose.
Subject demographics are provided in the Supplemental Infor-
mation. Major outcome measures included serum free carnitine
and acylcarnitines, substrate oxidation measured in vitro using
biopsied muscle specimens, and whole body glucose homeo-
stasis assessedby theHOMA insulin resistance index. In Figure 7
results are presented for the entire cohort grouped together, and
after stratifying subjects according to their HOMA-IR upon
enrollment, using a conservative cut off of 1.5 (Dvorak et al.,
1999). Six months of L-carnitine supplementation increased
circulating levels of free carnitine and acetylcarnitine 26% and
54%, respectively (Figures 7A and 7B). Whereas the intervention
did not appear to change whole body glucose control in the
insulin sensitive subgroup, the HOMA-IR index decreased 50%
in the insulin-resistant group from an average of 3.9 to 1.8 (Fig-
ure 7C), due to lowering of both plasma glucose and insulin
levels (Figures 7D and 7E).
Similar to the animal and cell-based studies, enhanced
acetylcarnitine efflux in the insulin-resistant subjects was
accompanied by increased PDH activity measured in muscle
homogenates (Figure 7F). When all subjects were grouped
together, in vitro oxidation rates of [1-14C]palmitate (Figure 7G)
and [2-14C]pyruvate (Figure 7H) to 14CO2 were lower after six
months of supplementation, whereas incomplete fat oxidation
to ASM was unchanged (not shown). The trends were similar in
the low and high HOMA groups, although statistical significance
was achieved only in the former. These outcomes resembled
the effects of CrAT overexpression in human myocytes and are
consistent with enhancedmitochondrial efflux of acetylcarnitine.
Metabolic flexibility assays were performed in vitro bymeasuring
the capacity of pyruvate and palmitate to compete with and
inhibit oxidation of [1-14C]palmitate and [2-14C]pyruvate, respec-
tively. Fitting with our previous animal work (Noland et al., 2009),
nutrient-induced substrate switching was blunted in the insulin-
resistant group and trended toward an improvement after
L-carnitine therapy. Notably, these in vitro assays were
performed with a surplus of L-carnitine, implying that the sup-
plementation regimen replenished the mitochondrial pool of
free carnitine and/or caused mitochondrial remodelling at
some other level.CDISCUSSION
The impetus for the current investigation stemmed from
mounting evidence linking insulin resistance to aberrant carnitine
metabolism, coupled with recent studies showing that carnitine
supplementation promotes CrAT-mediated acetylcarnitine efflux
and improves metabolic outcomes in obese rodents (Noland
et al., 2009; Power et al., 2007). Whereas decades of intense
research have been dedicated to understanding the roles of
carnitine and CPT1 in regulating fat oxidation, the metabolic
function of CrAT and the physiological relevance of acetylcarni-
tine efflux have remained comparatively understudied. Results
described herein now provide compelling evidence that CrAT
does indeed play an indispensable role in defending whole
body glucose homeostasis. Thus, muscle-specific ablation of
CrAT caused systemic glucose intolerance, interfered with
insulin effectiveness and blunted the normal postprandial rise
in glucose oxidation.
The primary substrate of CrAT, acetyl-CoA, holds a prominent
position in intermediary metabolism as the universal end product
of fatty acid, glucose and amino acid oxidation. As its major
metabolic fate, acetyl-CoA typically enters the tricarboxylic
acid (TCA) cycle where it drives production of reducing equiva-
lents that in turn fuel the mitochondrial electron transport chain.
Our findings suggest that CrAT functions as an outlet during
conditions wherein the production of short chain acyl-CoAs
exceeds TCA cycle flux. This could occur during the transition
from fasting to feeding; from rest to vigorous exercise and vice
versa; or in a chronically overfed state (Koves et al., 2008; New-
gard et al., 2009; Thyfault et al., 2010). Although a role for CrAT in
regulating mitochondrial acetyl-CoA/CoA balance and PDH
activity had been suggested previously (Uziel et al., 1988); here-
tofore, this possibility had not undergone rigorous experimental
testing, and the importance of the CrAT reaction at a systemic
level was unknown. In the current study crat deficiency resulted
in abnormal fuel selection, evident in whole animals and in iso-
lated mitochondria, and a corresponding decay in systemic
glucose homeostasis. These disruptions in energy metabolism
were associated with aberrant control of PDH activity. Thus,
loss of CrAT function completely obviated carnitine-mediated
stimulation of PDH activity in muscle mitochondria while also
hampering the capacity of pyruvate to compete with and inhibit
fatty acid oxidation. Notably, the latter outcome bears strong
resemblance to mitochondria from obese rats, which failed to
reduce fat oxidation in response to a pyruvate challenge (Noland
et al., 2009). These findings suggest that deficits in CrAT activity
might contribute to diet-induced metabolic inflexibility by exac-
erbating the glucose-fatty acid cycle as originally described by
(Randle et al., 1963).
The Randle hypothesis predicts that acetyl-CoA molecules
derived from glucose and lipid substrates compete for entry
into the TCA cycle. When b-oxidation increases, the mitochon-
drial pool of acetyl-CoA expands and inhibits PDH activity and
glycolytic flux. This is an appropriate response during fasting
conditions when glucose sparing becomes critical for survival.
By contrast, the early phases of refeeding are characterized by
an ample supply of both glucose and fatty acid fuel, and the
meal-induced rise in pancreatic insulin secretion serves as
a fundamental ‘‘signal of plenty’’ that encourages peripheralell Metabolism 15, 764–777, May 2, 2012 ª2012 Elsevier Inc. 771
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Figure 6. CrAT Counterregulates Glucose and Fatty Acid Metabolism in Primary Human Skeletal Myocytes
(A–F) Treatment of primary human skeletal myotubes with rAd-shCrat lowered CrAT activity and acetylcarnitine efflux into the culture media (A), increased
oxidation of 100 mM [1-14C]oleate to CO2 and decreased uptake of [
3H]-2-deoxy-glucose (B) as compared to the rAd-shLuc control. Treatment of myotubes
treated with increasing doses of rat CrAT (rAd-shCrat) increased CrAT activity and lowered complete oxidation (14CO2) of 100 mM [1-
14C]oleate without affecting
incomplete oxidation (acid soluble metabolites; ASM). Overexpression of CrAT increased acetylcarnitine efflux into the culture medium and increased PDH
activity measured in cell lysates (D). Cellular levels of glucose-derived acetylcarnitine was measured after 4 hr exposure to [13C6]glucose/[
13C3]pyruvate mixture
(5 mM/0.1 mM) ± 100 mM palmitate (FA) (E). Fatty acid-derived acetylcarnitine (E) and medium/long chain acylcarnitines (F) were measured after 4 hr exposure to
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CrAT Regulates Metabolic Flexibilitytissues to re-engage in glucose catabolism. The prevailing view
of substrate switching under this circumstance centers on
nutrient repletion of the TCA cycle and a resultant surge in mito-
chondrial efflux of citrate, which is converted to cytosolic acetyl-
CoA and then malonyl-CoA via the sequential actions of citrate
lyase and acetyl-CoA carboxylase, respectively (Figure 6G). Ma-
lonyl-CoA in turn inhibits CPT1, thus restricting mitochondrial
uptake and oxidation of fatty acid (McGarry et al., 1991). Accord-
ing to this so-called ‘‘reverse Randle cycle,’’ the pathways gov-
erning glucose and fatty acid oxidation are reciprocally regulated
in a tightly coordinated fashion (Ruderman et al., 1999). The
current study now adds a new dimension to this model by
showing that CrAT-mediated acetylcarnitine efflux opposes the
Randle cycle and allows PDH activity to increasewithout a corre-
sponding rise in TCA cycle flux and/or a shutdown in CPT1
activity. We therefore surmise that CrAT affords a mechanism
to ease inhibition of PDH during the fasted to fed transition,
thereby facilitating a more rapid and efficient transition from fatty
acid to glucose oxidation. Conversely, CrAT deficiency imposes
a more rigid version of the Randle cycle, such that PDH is
rendered more sensitive to counter-regulation by b-oxidation.
In this scenario, the feeding-induced shift from lipid to glucose
oxidation depends heavily on the gatekeeping function of the
malonyl-CoA/CPT1 axis (Figure 6G).
Interestingly, impaired insulin action in the CratM/ mice was
not coupled to an overt defect in Akt phosphorylation. Thus, the
block in insulin responsiveness in these mice appears to reside
downstream of Akt, or alternatively, might be independent of
insulin signaling all together. A number of studies examining
the early phases of insulin resistance have likewise reported
discrepancies between physiological changes in insulin-stimu-
lated glucose disposal and activation of the canonical insulin
signaling pathway (Høeg et al., 2011; Hoy et al., 2009; Hoy
et al., 2007). The notion that pyruvate trafficking per se could
impact systemic glucose homeostasis is strengthened by
studies in mice lacking PDH kinase 4, which have increased
PDH activity and enhanced glucose tolerance (Jeoung and Har-
ris, 2008). These findings fit with a model of distributed flux
control wherein the barrier to muscle glucose uptake shifts
from the transport step to phosphorylation and metabolism
once the Glut4 transporters are mobilized by insulin or exercise
(Wasserman, 2009). Whereas the conventional view of muscle
glucose metabolism encompasses glucose oxidation, glycogen
storage, and glycerolipid synthesis, we found that PDH-derived
acetylcarnitine is readily exported from both isolated soleus
muscles and cultured human myocytes. Thus, acetylcarnitine
efflux might represent a quantitatively important means of[13C16]palmitate (100mM) in the presence of unlabeled glucose/pyruvate (5 mM
2–4 independent experiments. * Effect of CrAT silencing or overexpression (p <
(G) Proposed model of CrAT-mediated regulation of mitochondrial carbon traffi
mitochondria are confronted with a heavy influx of both glucose and fatty acid fuel
activity to increase despite high rates of b-oxidation. This eases the Randle effe
deficiency and/or carnitine insufficiency imposes a more rigid version of the R
dependent on the production of malonyl-CoA and resultant inhibition of CPT1. Ab
acylcarnitine translocase (CACT); carnitine palmitoyltransferase 1 (CPT1); carnitin
(CrAT); citrate synthase (CS); electron transport chain (ETC); inner mitochond
(LC-CoA); medium chain acyl-CoA (MC-CoA); outer mitochondrial membrance
acid (TCA).
Cglucose disposal that in essence allows rerouting of carbons
from muscle to other metabolically active tissues (Farrell et al.,
1986; Lligona-Trulla et al., 1997). Further studies are necessary
to fully delineate the ultimate energetic fate and function of circu-
lating acetylcarnitine.
Another important and perhaps paradigm-shifting concept
that emerges from this work is that carnitine positively regulates
both lipid and carbohydrate oxidation in muscle. These dual
actions of L-carnitine take effect through CPT1 and CrAT,
respectively, which access two discrete pools of acyl-CoA
substrates. In a previous study accumulation of long chain
acylcarnitines inmuscle of diabetic rats correspondedwith lower
free carnitine levels, raising suspicion that mild carnitine defi-
ciency might permit the initial steps of b-oxidation while selec-
tively compromising CrAT activity. Herein, we found that CrAT
mRNA expression is severely decreased in humans with type 2
diabetes; and earlier studies reported that CrAT specific activity
measured in vitro is inhibited by long chain acyl-CoAs (Chase,
1967). Taken together, these results suggest that metabolic
disease and/or chronic lipid exposure might compromise
mitochondrial acetylcarnitine efflux capacity. Also noteworthy,
the accumulation of medium and long chain acylcarnitines in
muscles from CratM/ mice resembles the metabolite profile
assayed in muscles from obese and/or diabetic rodents (Koves
et al., 2005; Koves et al., 2008; Noland et al., 2009), thus building
upon evidence linking glucose intolerance to overloaded mito-
chondria. Crat deficiency rendered the mitochondria more
vulnerable to nutrient-induced stress and likewise increased
susceptibility to diet-induced metabolic dysfunction (Figure 2);
whereas carnitine therapy appears to mitigate this stress by
shunting surplus acetyl-CoA toward the CrAT reaction. In the
human pilot study carnitine therapy was most effective in
subjects with the highest HOMA index, suggesting that nutri-
tional and/or pharmacological strategies aimed at increasing
acetylcarnitine efflux might benefit prediabetic patients. These
findings are consistent with three previous reports showing
that intravenous infusions of L-carnitine improved insulin sensi-
tivity (measured by hyperinsulinemic euglycemic clamps) in
diabetic subjects (Capaldo et al., 1991; Giancaterini et al.,
2000; Mingrone et al., 1999). Surprisingly, the antidiabetic
potential of chronic L-carnitine supplementation has yet to be
rigorously tested in insulin-resistant humans. Our results now
provide strong justification for larger scale trials.
Lastly, whereas this investigation highlighted the interplay
between acetylcarnitine efflux and PDH activity, the regulatory
functions of CrAT are likely to extend beyond pyruvate metabo-
lism. Acetyl-CoA and other short chain acyl-CoAs serve both as/0.1 mM). Data are expressed as mean ± SEM and are representative of
0.05) detected by Student’s t test.
cking and metabolic flexibility. During the early phases of refeeding, muscle
. By permitting mitochondrial efflux of excess acetyl moieties, CrAT allows PDH
ct and facilitates a rapid transition from fatty acid to glucose oxidation. CrAT
andle cycle, wherein feeding-induced stimulation of PDH activity is heavily
breviations: Acetyl-CoA carboxylase (ACC); acetylcarnitine (C2-AC); carnitine
e palmitoyltransferase 2 (CPT2); citrate lyase (CL); carnitine acetyltransferase
rial membrane (imm); long chain acylcarnitine (LCAC); long chain acyl-CoA
(omm); oxaloacetic acid (OAA); pyruvate dehydrogenase (PDH); tricarboxylic
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Figure 7. Carnitine Supplementation Improves Glucose Homeostasis in Insulin-Resistant Humans
(A–H) Older aged human subjects (n = 14) with modestly elevated fasting blood glucose levels received supplemental L-carnitine (2 g/day) for 6 months. Fasting
serum samples were collected pre- and postintervention for measurement of free carnitine (A), acetylcarnitine (B), HOMA (C), glucose (D), and insulin (E). Tissue
homogenates prepared from vastus lateralis biopsies were used to measure PDH activity with 5 mM [1-14C]pyruvate (F). Substrate switching was determined by
measuring oxidation of 50mM [1-14C]palmitate (G) or 5 mM [2-14C]pyruvate (H) to 14CO2 in the absence or presence of the unlabeled competing substrate (5 mM
pyruvate or 100mMpalmitate, respectively). Results were stratified according to HOMA at enrollment, using a cut off of 1.5; n = 8 below and n = 6 above. * Effect of
carnitine supplementation analyzed by 1-tailed paired Student’s t test (p < 0.05).
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enzymes. In addition, reversible protein acetylation is emerging
as a central mechanism of nutrient sensing that in turn integrates
metabolic control at multiple levels (Hirschey et al., 2009;774 Cell Metabolism 15, 764–777, May 2, 2012 ª2012 Elsevier Inc.Schlicker et al., 2008). This developing area of research tempts
speculation that CrAT activity might have a broad-ranging
impact on the acetylation state of mitochondrial proteins.
Although the answers to this and a number of intriguing
Cell Metabolism
CrAT Regulates Metabolic Flexibilityquestions now await future investigation, our findings clearly
establish a heretofore unappreciated role for CrAT in controlling
whole body energy metabolism and raise promise that this
enzyme might have utility as a therapeutic target.EXPERIMENTAL PROCEDURES
Animal Studies
All procedures were approved by the Pennington Biomedical Research Center
Institutional Animal Care and Use Committee or the Duke University Institu-
tional Animal Care and Use Committee. Mice had free access to food and
water and were fed a standard chow (Purina Rodent Chow no. 5015, Purina
Mills, St. Louis, MO, USA) prior to being fed a semi-purified 10% fat diet
(Research Diets, D12450B) or a 45% fat diet (Research Diets, D12451). The
genetic strategy used for generating Cratfl/fl and CratM/ mice (Figure 1A) is
further detailed in Supplemental Experimental Procedures. Glucose and
insulin tolerance tests were performed as stated in the figure legends and
indirect calorimetry was measured as described (Albarado et al., 2004) after
mice were acclimated for 7 days to a 16-chamber CLAMS system (Columbus
Instruments, Columbus, OH, USA).Metabolic Profiling
Acylcarnitine measurements were made using flow injection tandem mass
spectrometry and methods described in (An et al., 2004; Millington et al.,
1990). [13C2]acetylcarnitine was quantified by standard isotope dilution meth-
odology using D3 acetylcarnitine as the internal standard after correcting for
the natural abundance of the M+1peak of the [13C2]acetylcarnitine peak.
This correction was determined empirically from a spectrum of [13C2]acetyl-
carnitine with no added internal standard. Acyl-CoAs were extracted from
heart tissue and analyzed according to methods described in Supplemental
Information. Plasma triacylglycerols, nonesterified fatty acids and insulin
were measured using kits from Sigma (#337-B), Wako Chemicals and Linco
Research, Inc., respectively.Enzyme Activity Assays
Citrate synthase activity was assessed using a colorimetric assay (Srere,
1969). This assay was adapted for measurement of CrAT activity. Baseline
measurements (2 min) were obtained using 10 ml of sample incubated in
190 ml reaction buffer (50mM Tris-HCl, 1M EDTA, 0.45mM acetyl-CoA,
0.1mM DTNB; pH = 7.8). CrAT specific activity was determined by measuring
the rate of reduction of DTNB (412 nm) by the free CoA liberated from acetyl-
CoA after adding 5mM L-carnitine and monitoring for 10 min.Substrate Oxidation and Mitochondrial Function
Mitochondria were isolated from mixed gastrocnemius muscles as described
in Supplemental Experimental Procedures and substrate oxidation experi-
ments were performed as described (Kim et al., 2002). PDH activity was
assessed ± 5mM L-carnitine by capturing 14CO2 from 1mM [1-
14C]pyruvate,
whereas palmitate oxidation was determined as 14CO2 released from
100 mM or 300 mM [1-14C]palmitate in the presence of 0-10mM pyruvate.
IC50 values for the inhibitory effect of pyruvate on palmitate oxidation were
determined using GraphPad Prism software (LaJolla, CA) after normalization
to basal rates followed by log transformation [X = log(X)] of the pyruvate
concentrations. Respiratory function was evaluated after mitochondrial resus-
pension in 0.5mg/ml inMiR05 respiration media (Boushel et al., 2007) using BD
Oxygen Biosensor plates (BD Biosciences, MA) as detailed in Supplemental
Experimental Procedures.Isolated Muscle Incubations
[1-14C]oleate oxidation in isolated soleus muscles was measured using
methods adapted from (Muoio et al., 1999) as detailed in the figure legends
and Supplemental Information. A similar protocol was followed for tracking
metabolism of [13C6]glucose, except muscles were preincubated in KHB +
0.2mM oleate:palmitate (1:1) bound to 1% BSA, followed by incubation in
the same buffer + 10 mM [13C6]glucose ± 100nM insulin.CCell Culture Studies
Primary human skeletal myocytes were grown and differentiated (Muoio et al.,
2002) in medium supplemented with 100 mM L-carnitine. Cytomegalovirus
(CMV) promoter-driven recombinant adenoviruses encoding either b-galacto-
sidase (rAdCMV-b-gal) or Myc-tagged rat carnitine acetyltransferase
(rAdCMV-Crat) were constructed, amplified, and purified according to (Becker
et al., 1994). Silencing of CrAT was accomplished using a siRNA target
sequence of 50-GCU CCG AUU UGC UGC CAA A-30. H1 promoter-driven
adenoviruses containing the siRNA sequences for luciferase (rAdH1-shLuc)
and Crat (rAdH1-shCrat) were constructed as described by (Odegaard et al.,
2010). On differentiation day 3, myotubes were exposed to 2 3 109 O.D./cm2
rAdCMV-Crat (unless otherwise noted) or 1.1 3 1010 O.D./cm2 rAdH1-shCrat
for 24 hr. Metabolic analyses were performed 3 days after virus treatment.
PDH (Arumugamet al., 2010) andCrAT activities weremeasured in cell lysates.
Oxidation of [1-14C]oleate (Koves et al., 2008) wasmeasured during a 2 hr incu-
bation in a-MEM. Glucose uptake was measured after 2 hr serum starvation in
a-MEM, followed by a preincubation for 30 min at 37C and then a 1 hr incu-
bation in uptake medium (a-MEM, [3H]-2-deoxyglucose (0.5mCi/ml; 11mM),
1mM L-carnitine) at 37C. Cells were washed in ice cold buffer (PBS +
20mM glucose), and lysates underwent scintillation counting. Nonspecific
background counts were estimated from myotubes treated with 40mM
cytochalasin B. Stable isotope tracer studies were performed using a-MEM
containing [13C6]glucose/[
13C3]pyruvate (5mM/0.1mM) ± palmitate (100mM/
0.14% BSA), or similar concentrations of [13C16]palmitate with glucose/pyru-
vate present. Cell lysate and media samples were collected after 4 hr and
analyzed by mass spectrometry.
Protein Expression
Tissue lysates were prepared using protease and phosphatase inhibitors
(Sigma-Aldrich, St. Louis, MO,). Protein concentrations were determined using
the Pierce BCA protein assay (Thermo Fisher Scientific Inc., Rockford, IL).
Proteins were separated on Criterion gels (Bio-Rad, Hercules, CA) and trans-
ferred to nitrocellulose membranes. Blots were blocked with 5% milk and
exposed to primary antibodies to detect: CrAT (generously provided by Fausto
Hegardt); total Akt, Akt pThr308, and Akt pSer473 (Cell Signaling, Danvers, MA);
PDH-E1a and electron transport chain complexes I, II, and V (MitoSciences,
Eugene, OR); PDH-E1a pSer232, PDH-E1a pSer293 and PDH-E1a pSer300
(Calbiochem, San Diego, CA); and citrate synthase (Alpha Diagnostics
International, San Antonio, TX). Proteins were visualized using horseradish
peroxidase-conjugated immunoglobulin G antibodies and ECL Plus chemilu-
minescence detection reagent with band intensity being quantified using
ImageQuant software (Amersham Biosciences). MemCode (Pierce, Rockford,
IL) protein staining served as a loading control for each blot.
Human Carnitine Supplementation
The experimental protocol was approved by the Duke University Institutional
Review Board. Subjects (n = 14) responded to ads placed in local papers
and were screened for eligibility. Inclusion criteria were age R 60, BMI
25-35.4, fasting blood glucose 95-125 mg/dl, HDL < 40 for men and < 45 for
women and exercise < two times per week. Upon enrollment subjects were
started on 2 g/day oral L-carnitine for six months. Compliance was monitored
by phone call-ins. At enrollment and upon completion of the study overnight
fasting blood samples were collected for measurement of glucose, insulin,
free carnitine and acetylcarnitine levels. Muscle biopsy specimens were
used for metabolic assays performed in tissue homogenates as detailed in
the figure legend.
Statistical Analysis
Data are presented as mean ± SEM. Results of animal studies were analyzed
by two-way ANOVA followed by pair-wise multiple comparison procedures
with a Student Newman–Keuls test to evaluate effects of genotype, diet or their
interaction using SigmaStat for Windows version 2.03 (SPSS, Chicago, IL,
USA). Mitochondrial metabolism studies and isolated muscle incubation
experiments were analyzed using a two-way repeated-measures ANOVA
with Bonferroni post hoc analysis (GraphPad Prism, La Jolla, CA). A Student’s
t test was used for studies comparing two groups. Statistical significance was
established a priori at p < 0.05.ell Metabolism 15, 764–777, May 2, 2012 ª2012 Elsevier Inc. 775
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